MedPath

Melatonin Supplementation in Postmenopausal Women With H. Pylori-associated Dyspepsia

Not Applicable
Completed
Conditions
Melatonin Deficiency
Interventions
Registration Number
NCT04352062
Lead Sponsor
Medical University of Lodz
Brief Summary

Background: The aim of the study was to assess the role of melatonin in chronic dyspepsia in this group of women, with consideration of Helicobacter infection. Methods: The study comprised 152 subjects Including 30 healthy women (group I), 60 women with asymptomatic H.pylori infection (group II), and 64 women H. pylori infected with chronic dyspepsia(group III). Endoscopic examination, histological assessment of gastric end duodenal mucosa, urease breath test(UBT-13C), and serum levels of 17-β-estradiol, follicle stimulating hormone, melatonin and urinary concentration of 6-sulfatoxymelatonin were determined by immunoenzymatic method. In group III - 14-day antibacterial treatment was introduced with pantoprazole, amoxicillin and levofloxacin. Afterward, in 32 women was administered placebo(group IIIa), and in 32 women (group IIIb) melatonin at a dose 1 m/morning and 3 mg/at bedtime, for six months.

Detailed Description

Background:Dyspeptic syndrome in the form of epigastric pain are particularly frequent in postmenopausal women. The aim of the study was to assess the role of melatonin in chronic dyspepsia in this group of women, with consideration of Helicobacter infection. Methods: The study comprised 152 subjects Including 30 healthy women (group I), 60 women with asymptomatic H.pylori infection (group II), and 64 women H. pylori infected with chronic dyspepsia(group III). Endoscopic examination, histological assessment of gastric end duodenal mucosa, urease breath test(UBT-13C), and serum levels of 17-β-estradiol, follicle stimulating hormone, melatonin and urinary concentration of 6-sulfatoxymelatonin were determined by immunoenzymatic method. In group III - 14-day antibacterial treatment was introduced with pantoprazole, amoxicillin and levofloxacin. Afterward, in 32 women was administered placebo(group IIIa), and in 32 women (group IIIb) melatonin at a dose 1 m/morning and 3 mg/at bedtime, for six months.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
152
Inclusion Criteria

Patients with

  • Epigastric pain of a hunger nature
  • Pain at night in the epigastric region
  • Increased appetite
Exclusion Criteria

Patients with

  • Functional or inflammatory diseases of the gastrointestinal tract liver and pancreas
  • Metabolic, allergic and mental disease
  • Hormone replacement therapy

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Placeboplacebo1 tablet twice daily (period 6 months)
Helicobacter pylori infected groupPantoprazole 40mgPantoprazole 2 x 40mg (twice daily) Amoxicyllin 2 x 1000mg (twice daily) Lovofloxacin 2 x 500mg (twice daily)
Helicobacter pylori infected groupLevofloxacin 500mgPantoprazole 2 x 40mg (twice daily) Amoxicyllin 2 x 1000mg (twice daily) Lovofloxacin 2 x 500mg (twice daily)
Treatment GroupMelatoninMelatonin ( 5-Methoxy-N-Acetyltryptamine) at dose 1mg/morning and 3mg/at bedtime (period 6 months)
Helicobacter pylori infected groupAmoxicillinPantoprazole 2 x 40mg (twice daily) Amoxicyllin 2 x 1000mg (twice daily) Lovofloxacin 2 x 500mg (twice daily)
Primary Outcome Measures
NameTimeMethod
10 point Visual Analogue Scale (VAS) of Dyspeptic symptoms6 months

scale that access severity of Dyspeptic symptoms such as: epigastric pain of hunger nature and pain in the epigastric region at night (intensity measured from 1 to 10 points)

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Department of Clinical Nutrition and Gastroenterological Diagnostics Medical University of Lodz

🇵🇱

Łódź, Poland

© Copyright 2025. All Rights Reserved by MedPath